Trial Profile
A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 May 2013 Planned end date changed from 1 Jan 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 17 May 2012 New source identified and integrated (SOL12063C: OHSU Knight Cancer Institute).
- 02 Dec 2011 Planned end date changed from 1 May 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.